Abivax SA
Abivax SA (ABVX): 23 pipeline candidates · 1 upcoming catalyst · ~25 mo cash runway · 17 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
24.8 months
0% dilution
Lead: Phase 3
23 candidates
1 upcoming, next in ~1413d
N/A
A transparent, data-derived signal for Abivax SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.1B
Cash
$38.1M
Quarterly Burn
$23.2M
Runway
24.8 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| abx464 | Phase 3 |
| ABX464 | Phase 3 |
| obefazimod | Phase 2 |
| Obefazimod | Phase 2 |
| Obefazimod 50 mg Capsule | Phase 2 |
| obefazimod mini | Phase 2 |
| obefazimod mini | Phase 2 |
| obefazimod mini | Phase 2 |
| obefazimod mini | Phase 2 |
| obefazimod mini | Phase 2 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
247
Total value held
$4.04B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 1,757,658 | $196.0M |
| morgan stanley | 1,704,958 | $189.8M |
| caligan partners lp | 1,461,924 | $162.8M |
| adar1 capital management, llc | 1,438,019 | $160.1M |
| citadel advisors llc | 1,339,038 | $149.1M |
| westfield capital management co lp | 1,322,938 | $147.3M |
| fmr llc | 1,286,373 | $143.2M |
| susquehanna international group, llp | 1,284,782 | $143.1M |
| eversept partners, lp | 934,423 | $104.0M |
| baker bros. advisors lp | 875,796 | $97.5M |
Showing top 10 of 247 institutional holders of Abivax SA. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Abivax SA's pipeline?
Abivax SA (ABVX) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Abivax SA's lead drug candidate?
Abivax SA's most advanced tracked candidate is abx464 (Phase 3) for Ulcerative Colitis; COVID-19; Rheumatoid Arthritis.
What is Abivax SA's next catalyst?
Abivax SA's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet" — expected May 1, 2030.
What is Abivax SA's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Abivax SA has approximately 24.8 months of cash runway.
What is Abivax SA's market capitalization?
Abivax SA's market capitalization is approximately $8.1B.
Get the full picture on Abivax SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.